Wenhu Zhan

发表

Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.

S. Yuan, Yanyang Li, F. Jiang, 2012, Bioorganic & medicinal chemistry.

Improvement of asparagine ethylenediamines as anti-malarial Plasmodium-selective proteasome inhibitors.

P. Rosenthal, P. Singh, P. Meinke, 2019, Journal of medicinal chemistry.

Design, Synthesis, and Optimization of Macrocyclic Peptides as Species-Selective Antimalaria Proteasome Inhibitors.

J. Vendôme, M. Michino, C. Nathan, 2022, Journal of medicinal chemistry.

Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity.

Qiaojun He, Yongzhou Hu, Xiaowu Dong, 2021, Journal of medicinal chemistry.

Phenotypic Screening-Based Identification of 3,4-Disubstituted Piperidine Derivatives as Macrophage M2 Polarization Modulators: An Opportunity for Treating Multiple Sclerosis.

Qiaojun He, Bo Yang, Yongzhou Hu, 2019, Journal of medicinal chemistry.

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors

J. Chen, Xiaowu Dong, Wenting Du, 2015, Chemical biology & drug design.

Structure of the human UBR5 E3 ubiquitin ligase

Huilin Li, Wenhu Zhan, G. Lin, 2022, bioRxiv.

Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.

Bo Yang, Yongzhou Hu, Xiaodong Ma, 2016, European journal of medicinal chemistry.

Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-based Design.

Qiaojun He, Bo Yang, Yongzhou Hu, 2019, Journal of medicinal chemistry.

Structure-based design, synthesis and biological evaluation of diphenylmethylamine derivatives as novel Akt1 inhibitors.

Bo Yang, Xiaowu Dong, L. Zhang, 2014, European journal of medicinal chemistry.

Environmentally Ultrasensitive Fluorine Probe to Resolve Protein Conformational Ensembles by 19F NMR and Cryo-EM

D. Eliezer, O. Boudker, C. Bracken, 2023, bioRxiv.

Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.

W. Hu, Zhenglin Yao, Yanjin Zhao, 2012, Bioorganic & medicinal chemistry letters.

Integrating docking scores, interaction profiles and molecular descriptors to improve the accuracy of molecular docking: toward the discovery of novel Akt1 inhibitors.

Bo Yang, Xiaowu Dong, Yongzhou Hu, 2014, European journal of medicinal chemistry.

Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance

M. Foley, P. Rosenthal, P. Bhanot, 2018, Proceedings of the National Academy of Sciences.

Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome

H. Zhang, M. Bogyo, D. Fidock, 2023, Cell chemical biology.

Structure-Activity Relationship Studies of Antimalarial Plasmodium Proteasome Inhibitors─Part II.

M. Foley, J. Vendôme, N. Liverton, 2023, Journal of medicinal chemistry.

Structure-Activity Relationships of Noncovalent Immunoproteasome β5i-Selective Dipeptides.

Xiaojing Ma, C. Nathan, J. Salmon, 2020, Journal of medicinal chemistry.

Artemisinin-based hybrids produce intracellular proteasome inhibitors that overcome resistance in Plasmodium falciparum

C. Nathan, Changmei Yang, L. Kirkman, 2021, bioRxiv.

Discovery of Highly Selective Inhibitors of the Human Constitutive Proteasome β5c Chymotryptic Subunit.

J. Azzi, G. Sukenick, Wenhu Zhan, 2023, Journal of medicinal chemistry.

Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes

Huilin Li, C. Nathan, Kaiming Zhang, 2017, Nature Communications.

Selective Phenylimidazole-based Inhibitors of the Mycobacterium tuberculosis Proteasome.

M. Foley, Huilin Li, M. Michino, 2019, Journal of medicinal chemistry.

Dual-pharmacophore artezomibs hijack the Plasmodium ubiquitin-proteasome system to kill malaria parasites while overcoming drug resistance.

H. Zhang, A. Waters, C. Nathan, 2023, Cell chemical biology.

Development of a highly selective Plasmodium falciparum proteasome inhibitor with anti-malaria activity in humanized mice.

P. Rosenthal, J. Vendôme, M. Michino, 2021, Angewandte Chemie.

Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.

M. Foley, Huilin Li, J. Vendôme, 2021, Journal of medicinal chemistry.

Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues.

Xiaodong Ma, Xiaoqing Lv, Henian Wang, 2023, Journal of medicinal chemistry.

Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes

Huilin Li, C. Nathan, Kaiming Zhang, 2017, Nature Communications.

Structures revealing mechanisms of resistance and collateral sensitivity of Plasmodium falciparum to proteasome inhibitors

F. Gamo, Benigno Crespo, L. Kirkman, 2023, Nature communications.

Protocol for analysis of intracellular conversion of artezomib molecules into new proteasome inhibitors in Plasmodium falciparum parasites

L. Kirkman, Wenhu Zhan, G. Lin, 2024, STAR protocols.